NCT04632589

Losartan for Improved Vascular Endothelial Function After Preeclampsia

Angiotensin II Receptor Inhibition to Improve Microvascular Function in Women Who Have Had Preeclampsia

• Status: Completed
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Anna Stanhewicz, PhD · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs is unclear but may be related to blood vessel damage and increased inflammation that occurs during the preeclamptic pregnancy and persists postpartum. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage and to test whether taking a medication that blocks angiotensin II receptors (losartan) decrease these negative effects in women who have had preeclampsia. Identification of these mechanisms and treatment strategies may lead to better clinical management,of cardiovascular disease risk in these women. In this study we use the blood vessels in the skin as a representative vascular bed. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickle-sized area of the skin in women who have had preeclampsia. We make these measurements after the subjects take a placebo and after they take losartan (an angiotensin II receptor blocker) to test whether this treatment improves vascular function in these women. As a compliment to these measurements, we also draw blood from the subjects and isolate the inflammatory cells to test how sensitive their inflammatory responses are following the placebo and the losartan treatment.

Conditions

• Preeclampsia Postpartum

Interventions

Type	Name	Description
DRUG	Losartan Potassium	subjects ingest 50mg losartan potassium tablet daily for 6 weeks
DRUG	Placebo	subjects ingest placebo tablet daily for 6 weeks

Timeline

• Start date: 2020-11-22
• Primary completion: 2024-06-30
• Completion: 2025-03-13
• First posted: 2020-11-17
• Last updated: 2025-07-10
• Results posted: 2025-07-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study